Limitations, agreements, and source contact

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 · Source last updated 2017-01-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

Planned accrual: 20. Sponsor withdrew support soon after one enrollment. Accrual was terminated; analysis unable to be performed. Participant stopped treatment after 14 cycles due to progressive lymphadenopathy; entered another clinical trial.

point Of Contact

email

lubomir.sokol@moffitt.org

organization

H. Lee Moffitt Cancer Center and Research Institute

phone

813-745-8212

title

Dr. Lubomir Sokol

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice